Dal Cason, TA. A re-examination of the mono-methoxy positional ring isomers of amphetamine, methamphetamine and phenyl-2-propanone. Forensic Sci. Int., 1 Jan 2001, 119 (3), 168–194. 678 kB. https://doi.org/10.1016/S0379-0738(00)00425-4
Błachut, D; Wojtasiewicz, K; Czarnocki, Z; Szukalski, B. The analytical profile of some 4-methylthioamphetamine (4-MTA) homologues. Forensic Sci. Int., 20 Nov 2009, 192 (1–3), 98–114. 683 kB. https://doi.org/10.1016/j.forsciint.2009.08.009
Steele, TD; Katz, JL; Ricaurte, GA. Evaluation of the neurotoxicity of N-methyl-1-(4-methoxyphenyl)-2-aminopropane (para-methoxymethamphetamine, PMMA). Brain Res., 4 Sep 1992, 589 (2), 349–352. 554 kB. https://doi.org/10.1016/0006-8993(92)91298-S
Vevelstad, M; Øiestad, EL; Middelkoop, G; Hasvold, I; Lilleng, P; Delaveris, GJM; Eggen, T; Mørland, J; Arnestad, M. The PMMA epidemic in Norway: Comparison of fatal and non-fatal intoxications. Forensic Sci. Int., 10 Jun 2012, 219 (1–3), 151–157. 332 kB. https://doi.org/10.1016/j.forsciint.2011.12.014
EMCDDA. Report on the risk assessment of PMMA, European Monitoring Centre for Drugs and Drug Addiction, Mar 2003. 377 kB. Pages cropped (as was intended but never done, apparently)
Nakanishi, K; Miki, A; Zaitsu, K; Kamata, H; Shima, N; Kamata, T; Katagi, M; Tatsuno, M; Tsuchihashi, H; Suzuki, K. Cross-reactivities of various phenethylamine-type designer drugs to immunoassays for amphetamines, with special attention to the evaluation of the one-step urine drug test Instant-View™, and the Emit® assays for use in drug enforcement. Forensic Sci. Int., 10 Apr 2012, 217 (1–3), 174–181. 397 kB. https://doi.org/10.1016/j.forsciint.2011.11.003
Bustamante, D; Diaz-Véliz, G; Paeile, C; Zapata-Torres, G; Cassels, BK. Analgesic and behavioral effects of amphetamine enantiomers, p-methoxyamphetamine and N-alkyl-p-methoxyamphetamine derivatives. Pharmacol. Biochem. Behav., 1 Oct 2004, 79 (2), 199–212. 404 kB. https://doi.org/10.1016/j.pbb.2004.06.017
Clark, CC. The identification of methoxy-N-methylamphetamines. J. Forensic Sci., 1 Oct 1984, 29 (4), 1056–1071. 423 kB. https://doi.org/10.1520/JFS11772J
Katagi, M; Tsuchihashi, H. Update on clandestine amphetamines and their analogues recently seen in Japan. J. Health Sci., 2002, 48 (1), 14–21. 181 kB. https://doi.org/10.1248/jhs.48.14
Bailey, K; By, AW; Legault, D; Verner, D. Identification of the N-methylated analogs of the hallucinogenic amphetamines and some isomers. J. Assoc. Off. Anal. Chem., 1975, 58 (1), 62–69. 2.0 MB.
Lurie, Y; Gopher, A; Lavon, O; Almog, S; Sulimani, L; Bentur, Y. Severe paramethoxymethamphetamine (PMMA) and paramethoxyamphetamine (PMA) outbreak in Israel. Clin. Toxicol., 1 Jan 2012, 50 (1), 39–43. 93 kB. https://doi.org/10.3109/15563650.2011.635148
Glennon, RA. Bath salts, mephedrone, and methylenedioxypyrovalerone as emerging illicit drugs that will need targeted therapeutic intervention. Adv. Pharmacol., 2014, 69, 581–620. 564 kB. https://doi.org/10.1016/B978-0-12-420118-7.00015-9
Segawa, H; Iwata, YT; Yamamuro, T; Kuwayama, K; Tsujikawa, K; Kanamori, T; Inoue, H. Differentiation of ring-substituted regioisomers of amphetamine and methamphetamine by supercritical fluid chromatography: Differentiation of ring-substituted regioisomers by supercritical fluid chromatography. Drug Test. Analysis, 1 Mar 2017, 9 (3), 389-398. 1.3 MB. https://doi.org/10.1002/dta.2040
Ogino, M; Naiki, T; Orui, H; Kosone, K; Yamazaki, M. Study of method for identifying phenethylamine drugs. JCCL, 11 Feb 2011, 50, 63-82. 627 kB. Retrieved from http://www.customs.go.jp/ccl_search/e_info_search/drugs/r_50_08_e.pdf
EMCDDA. New drugs in Europe, 2016, European Monitoring Centre for Drugs and Drug Addiction, 1 May 2017. 489 kB.
EMCDDA. New drugs in Europe, 2015, European Monitoring Centre for Drugs and Drug Addiction, 1 May 2016. 1.0 MB.
EMCDDA. New drugs in Europe, 2014, European Monitoring Centre for Drugs and Drug Addiction, 1 Jul 2015. 879 kB.
EMCDDA. New drugs in Europe, 2013, European Monitoring Centre for Drugs and Drug Addiction, 1 Jul 2014. 311 kB.
EMCDDA. New drugs in Europe, 2011, European Monitoring Centre for Drugs and Drug Addiction, 1 Apr 2012. 401 kB.
EMCDDA. New drugs in Europe, 2010, European Monitoring Centre for Drugs and Drug Addiction, 1 May 2011. 700 kB.
Hudson, AL; Lalies, MD; Baker, GB; Wells, K; Aitchison, KJ. Ecstasy, legal highs and designer drug use: A Canadian perspective. Drug Science, Policy and Law, 1 Jan 2014, 1, 2050324513509190. 230 kB. https://doi.org/10.1177/2050324513509190
Nagashima, M; Seto, T; Takahashi, M; Suzuki, J; Yasuda, I. Spectrum data of 4th Governor-designated drugs and the analyses of illegal drugs purchased Apr. 2006 – Mar. 2007. Ann. Rep. Tokyo Metr. Inst. P. H., 1 Jan 2007, 58 89–92. 935 kB. #PMMA LC,MS,NMR,IR,UV
Shulgin, AT. Basic Pharmacology and Effects. In Hallucinogens. A Forensic Drug Handbook; Laing, R; Siegel, JA, Eds., Academic Press, London, 2003; pp 67–137. 6.3 MB.
Nichols, DE. Medicinal chemistry and structure-activity relationships. In Amphetamine and its Analogs; Cho, AK; Segal, DS, Eds., Academic Press, San Diego, CA, 1 Jan 1994; pp 3–41. 6.9 MB.
Simmler, LD; Liechti, ME. Pharmacology of MDMA- and amphetamine-like new psychoactive substances. In Handbook of Experimental Pharmacology; , Springer Berlin Heidelberg, 1 Jan 2018; . 298 kB. https://doi.org/10.1007/164_2018_113
Takahashi, M; Nagashima, M; Suzuki, J; Seto, T; Yasuda, I; Yoshida, T. Creation and application of psychoactive designer drugs data library using liquid chromatography with photodiode array spectrophotometry detector and gas chromatography–mass spectrometry. Talanta, 15 Feb 2009, 77 (4), 1245–1272. 1.2 MB. https://doi.org/10.1016/j.talanta.2008.07.062 #PMMA
Nagashima, M; Seto, T; Takahashi, M; Suzuki, J; Yasuda, I. Spectrum data of the 3rd Governor-designated drugs and the analyses of uncontrolled drugs purchased Apr. 2005 – Mar. 2006. Ann. Rep. Tokyo Metr. Inst. P. H., 1 Jan 2006, 57 109–113. 394 kB. #PMMA